fails

JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) said that ocedurenone, under investigation for uncontrolled hypertension in chronic kidney disease patients, missed its primary endpoint in a phase 3 trial. That endpoint was change in systolic blood pressure from baseline to week 12. As a result, the Danish pharma isContinue Reading

Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) has discontinued a Phase 2 trial for its blockbuster arthritis therapy Tremfya in patients with an autoimmune disorder called giant cell arteritis after the study failed to meet the primary goal, according to updated data from a federal register ofContinue Reading

jetcityimage/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been surgically removed. Citing data from a Phase 3 trial called ADJUVANT BR.31, the company said Imfinzi did not demonstrateContinue Reading